

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JUL 02	LMEDLINE coverage updated
NEWS	3	JUL 02	SCISEARCH enhanced with complete author names
NEWS	4	JUL 02	CHEMCATS accession numbers revised
NEWS	5	JUL 02	CA/CAPplus enhanced with utility model patents from China
NEWS	6	JUL 16	CAPplus enhanced with French and German abstracts
NEWS	7	JUL 18	CA/CAPplus patent coverage enhanced
NEWS	8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS	9	JUL 30	USGENE now available on STN
NEWS	10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	11	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	12	AUG 13	CA/CAPplus enhanced with additional kind codes for granted patents
NEWS	13	AUG 20	CA/CAPplus enhanced with CAS indexing in pre-1907 records
NEWS	14	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	15	AUG 27	USPATOLD now available on STN
NEWS	16	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	17	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	18	SEP 13	FORIS renamed to SOFIS
NEWS	19	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	20	SEP 17	CA/CAPplus enhanced with printed CA page images from 1967-1998
NEWS	21	SEP 17	CAPplus coverage extended to include traditional medicine patents
NEWS	22	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	23	OCT 02	CA/CAPplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	24	OCT 19	BEILSTEIN updated with new compounds
NEWS	25	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	26	NOV 19	WPIX enhanced with XML display format
NEWS EXPRESS	19	SEPTEMBER 2007:	CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 17:39:55 ON 28 NOV 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 17:40:11 ON 28 NOV 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 27 NOV 2007 HIGHEST RN 956075-61-9

DICTIONARY FILE UPDATES: 27 NOV 2007 HIGHEST RN 956075-61-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10518496c.str



chain nodes :

11 12 13 14 15 17

ring nodes :

1 2 3 4 5 6 7

chain bonds :

11-12 12-13 12-14 13-15 13-17

ring bonds :

1-2 1-6 1-7 2-3 3-4 4-5 4-7 5-6

exact/norm bonds :

1-2 1-6 2-3 3-4 4-5 4-7 5-6 11-12 12-13 12-14 13-15 13-17

exact bonds :

1-7
isolated ring systems :
containing 1 :

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 11:CLASS 12:CLASS
13:CLASS 14:CLASS 15:Atom 16:CLASS 17:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 17:40:44 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 885 TO ITERATE

100.0% PROCESSED 885 ITERATIONS

32 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 15916 TO 19484

PROJECTED ANSWERS: 301 TO 979

L2 32 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 17:40:49 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 18856 TO ITERATE

100.0% PROCESSED 18856 ITERATIONS

587 ANSWERS

SEARCH TIME: 00.00.01

L3 587 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.10

172.31

FILE 'CAPLUS' ENTERED AT 17:40:53 ON 28 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 Nov 2007 VOL 147 ISS 23
FILE LAST UPDATED: 27 Nov 2007 (20071127/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>



=> s l3 full

L4 6 L3

=> d ibib abs hitstr tot

ACCESSION NUMBER: 2006:99752 CAPLUS
 DOCUMENT NUMBER: 144:171147
 TITLE: Process for preparing quinuclidinium carbamate derivatives
 INVENTOR(S): Prat Quinones, Maria; Busquets Baque, Nuria; Pujol Noguera, Ferran; Ibarzo Casamian, Francisco, Javier
 PATENT ASSIGNEE(S): Almirall Prodesfarma, SA, Spain
 SOURCE: PCT Int. Appl., 33 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006010452	A1	20060202	WO 2005-EP7424	20050708
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
ES 2246170	A1	20060201	ES 2004-1880	20040729
ES 2246170	B1	20070401		
EP 1781651	A1	20070509	EP 2005-762590	20050708
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
CN 101018786	A	20070815	CN 2005-80024812	20050708
PRIORITY APPLN. INFO.:			ES 2004-1880	A 20040729
			WO 2005-EP7424	W 20050708
OTHER SOURCE(S):	MARPAT 144:171147			
GI				



AB This invention relates to a new process for preparing carbamate derivs., such as I [R = (CH₂)_m-A-(CH₂)_n-B; R₁ = CH₂Ph, 2-, 3-furanyl, 2-, 3-thienyl, 2-, 3-furanylmethyl, 2-, 3-thienylmethyl, etc.; R₂ = Ph, CH₂Ph, alkyl, alkenyl, alkynyl, cycloalkyl, 2-, 3-furanylmethyl, 2-, 3-thienylmethyl, etc.; A = linking group, such as CH₂, CH:CH, CO, O, S, SO, SO₂, NH, etc.; B = CN, NO₂, alkyl, alkoxy cycloalkylmethyl, aryl, heteroaryl, etc.; m = 0-8; n = 0-4], by reacting, in a first step, a corresponding azabicyclic

alc. with a compound W-(CH₂)_m-A-(CH₂)_n-B (W = leaving group, such as Br) and reacting the product of this first step with an acylating agent G-CONR₁R₂ (G = leaving group, such as Cl). Thus, quinuclidinium carbamate II was prepared via refluxing Ph(CH₂)₃Br with (3R)-3-quinuclidinol in THF to form (3R)-3-hydroxy-1-(3-phenylpropyl)-1-azoniabicyclo[2.2.2]octane bromide in 100% yield, and subsequently, reacting the intermediate quinuclidinium alc. with PhCH₂N(Ph)COCl using NaH in DMF and mineral oil to give the desired quinuclidinium carbamate with 46% yield for the carbamoylation step.

IT 439908-03-9P 439908-55-1P 439908-92-6P

637744-69-5P


RL: SPN (Synthetic preparation); PREP (Preparation)

(process for preparing quinuclidinium carbamate derivs. useful as intermediates in pharmaceutical synthesis)

RN 439908-03-9 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-1-(3-phenylpropyl)-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439908-55-1 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[butylphenylamino]carbonyl]oxy]-1-(3-phenyl-2-propenyl)-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




● Br⁻

RN 439908-92-6 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[butylphenylamino]carbonyl]oxy]-1-[3-(2-thienyl)propyl]-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 637744-69-5 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(3-methylphenyl)[(2,4,5-trifluorophenyl)methyl]amino]carbonyloxy]-1-(3-phenylpropyl)-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br⁻

REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2004:2883 CAPLUS

DOCUMENT NUMBER: 140:59820

TITLE: Preparation of novel quinuclidine derivatives for therapeutic use in medicinal compositions as M3 muscarinic receptor antagonists

INVENTOR(S): Prat Quinones, Maria; Buil Alberro, Maria Antonia; Fernandez Forner, Maria Dolores

PATENT ASSIGNEE(S): Almirall Prodesfarma S.A., Spain

SOURCE: PCT Int. Appl., 82 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000840	A2	20031231	WO 2003-EP6472	20030618
WO 2004000840	A3	20040219		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
ES 2203327	A1	20040401	ES 2002-1439	20020621
ES 2203327	B1	20050616		
CA 2490082	A1	20031231	CA 2003-2490082	20030618
AU 2003279384	A1	20040106	AU 2003-279384	20030618
EP 1515968	A2	20050323	EP 2003-740284	20030618
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003012169	A	20050329	BR 2003-12169	20030618
CN 1675206	A	20050928	CN 2003-819327	20030618
JP 2005533799	T	20051110	JP 2004-514785	20030618
NZ 537252	A	20060728	NZ 2003-537252	20030618
MX 2004PA12272	A	20050408	MX 2004-PA12272	20041207
ZA 2004010211	A	20050906	ZA 2004-10211	20041217
NO 2005000217	A	20050318	NO 2005-217	20050113
US 2006094751	A1	20060504	US 2005-518496	20050919
PRIORITY APPLN. INFO.:			ES 2002-1439	A 20020621
			WO 2003-EP6472	W 20030618

OTHER SOURCE(S): MARPAT 140:59820

GI



AB Quinuclidine derivs., such as I and II [R = (CH₂)_m-A-(CH₂)_n-B; R₁ = unsubstituted, halo substituted, alkyl substituted, or cyano substituted Ph, 2-thienylmethyl, 2-thienyl, 2-furylmethyl, 2-furyl, 3-thienylmethyl, 3-thienyl, 3-furylmethyl, 3-furyl; R₂ = benzyl, phenethyl, 2-furylmethyl,

3-furylmethyl, 2-thienylmethyl or 3-thienylmethyl group or a straight or branched alkyl group having 3 or 8 carbon atoms, an alkenyl group having 3 to 8 carbons atoms, or a cycloalkyl group of 3 to 6 carbon atoms; A = CH₂, R₃C:CH, CH:CR₃, CO, O, S, SO, SO₂, NR₃, CR₃R₄; B = O₂CR₃, CO₂R₃, cyano, etc.; R₃, R₄ = H, alkyl, R₃R₄ = alicyclic ring; X⁻ = anion, such as Cl⁻, Br⁻, I⁻ or F₃CCO₂⁻; m = 0-8, n = 0-4], and pharmaceutical compns.

comprising them were prepared for use in therapy as antagonists of M₃ muscarinic receptors (no biol. testing data presented) and are claimed for use in the treatment of respiratory, urol. and gastrointestinal diseases. Thus, butylphenylcarbamic acid (3R)-1-azabicyclo[2.2.2]oct-3-yl ester was prepared in 22% yield by refluxing (R)-3-quinuclidinol in toluene with sodium for 2h and then adding butylphenylcarbamoyl chloride and refluxing for an addnl. 1 h. Pharmaceutical compns. containing the prepared

quinuclidines

were presented.

IT 385367-13-5P 385367-28-2P 385367-46-4P
385367-47-5P 439909-77-0P 439910-43-7P
637744-75-3P 637744-77-5P 637744-79-7P


RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of novel quinuclidine derivs. for therapeutic use in medicinal compns. as M₃ muscarinic receptor antagonists)

RN 385367-13-5 CAPLUS

CN Carbamic acid, phenyl(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 385367-28-2 CAPLUS

CN Carbamic acid, (3-fluorophenyl)[(3-fluorophenyl)methyl]-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-46-4 CAPLUS

CN Carbamic acid, (3-methylphenyl)[(2,4,5-trifluorophenyl)methyl]-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-47-5 CAPLUS

CN Carbamic acid, (3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439909-77-0 CAPLUS


CN Carbamic acid, phenyl(3-thienylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439910-43-7 CAPLUS


CN Carbamic acid, phenyl(phenylmethyl)-, 1-azabicyclo[2.2.1]hept-4-yl ester (9CI) (CA INDEX NAME)



RN 637744-75-3 CAPLUS

CN Carbamic acid, [(5-bromo-2-thienyl)methyl](2,4,5-trifluorophenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 637744-77-5 CAPLUS

CN Carbamic acid, (4-fluoro-2-methylphenyl)[(3-methyl-2-thienyl)methyl]-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 637744-79-7 CAPLUS

CN Carbamic acid, (3-fluoro-4-methoxyphenyl)(3-thienylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 17656-16-5P 385367-14-6P 385367-68-0P
 385367-71-5P 385367-72-6P 385367-73-7P
 385367-74-8P 385367-75-9P 385367-76-0P
 439907-53-6P 439907-55-8P 439907-57-0P
 439907-58-1P 439907-59-2P 439907-61-6P
 439907-63-8P 439907-65-0P 439907-67-2P
 439907-69-4P 439907-71-8P 439907-73-0P
 439907-75-2P 439907-77-4P 439907-79-6P
 439907-81-0P 439907-83-2P 439907-85-4P
 439907-87-6P 439907-89-8P 439907-90-1P
 439907-92-3P 439907-94-5P 439907-95-6P
 439907-97-8P 439907-99-0P 439908-00-6P
 439908-01-7P 439908-02-8P 439908-03-9P
 439908-04-0P 439908-06-2P 439908-08-4P
 439908-10-8P 439908-12-0P 439908-14-2P
 439908-16-4P 439908-18-6P 439908-20-0P
 439908-22-2P 439908-24-4P 439908-26-6P
 439908-28-8P 439908-30-2P 439908-32-4P
 439908-34-6P 439908-36-8P 439908-38-0P
 439908-40-4P 439908-42-6P 439908-43-7P
 439908-45-9P 439908-47-1P 439908-50-6P
 439908-52-8P 439908-54-0P 439908-55-1P
 439908-56-2P 439908-58-4P 439908-60-8P
 439908-62-0P 439908-64-2P 439908-66-4P
 439908-68-6P 439908-70-0P 439908-72-2P
 439908-74-4P 439908-76-6P 439908-78-8P
 439908-80-2P 439908-82-4P 439908-84-6P
 439908-86-8P 439908-87-9P 439908-88-0P
 439908-89-1P 439908-90-4P 439908-91-5P
 439908-92-6P 439908-93-7P 439908-94-8P
 439908-95-9P 439908-97-1P 439908-99-3P
 439909-01-0P 439909-03-2P 439909-05-4P
 439909-07-6P 439909-08-7P 439909-09-8P
 439909-10-1P 439909-11-2P 439909-12-3P
 439909-14-5P 439909-16-7P 439909-18-9P
 439909-20-3P 439909-22-5P 439909-24-7P
 439909-26-9P 439909-29-2P 439909-32-7P
 439909-34-9P 439909-36-1P 439909-39-4P
 439909-41-8P 439909-43-0P 439909-45-2P
 439909-47-4P 439909-49-6P 439909-51-0P
 439909-53-2P 439909-54-3P 439909-56-5P
 439909-58-7P 439909-60-1P 439909-62-3P
 439909-64-5P 439909-66-7P 439909-68-9P
 439909-70-3P 439909-72-5P 439909-75-8P
 439909-79-2P 439909-81-6P 439909-83-8P
 439909-85-0P 439909-87-2P 439909-89-4P
 439909-91-8P 439909-93-0P 439909-94-1P
 439909-95-2P 439910-19-7P 439910-21-1P
 439910-25-5P 439910-27-7P 439910-30-2P


439910-33-5P 439910-45-9P 637744-43-5P
 637744-64-0P 637744-67-3P 637744-68-4P
 637744-69-5P 637744-70-8P 637744-71-9P
 637744-72-0P 637744-76-4P 637744-78-6P
 637744-80-0P 637744-84-4P 637744-85-5P
 637744-89-9P 637744-90-2P 637744-91-3P
 637744-94-6P 637744-97-9P 637744-99-1P
 637745-13-2P 637745-15-4P 637745-17-6P
 637745-18-7P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of novel quinuclidine derivs. for therapeutic use in medicinal compns. as M3 muscarinic receptor antagonists)

RN 17656-16-5 CAPLUS


CN Carbamic acid, ethylphenyl-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)



RN 385367-14-6 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, iodide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● I⁻

RN 385367-68-0 CAPLUS

CN Carbamic acid, (cyclohexylmethyl)(2-fluorophenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-71-5 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-fluorophenyl)methyl]phenylamino]carbonyloxy]-1-methyl-, iodide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● I⁻

RN 385367-72-6 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[[(2-methylphenyl)(phenylmethyl)amino]carbonyloxy]-, iodide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● I⁻

RN 385367-73-7 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[[(2-methylphenyl)[(2,4,5-trifluorophenyl)methyl]amino]carbonyloxy]-, iodide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● I⁻

RN 385367-74-8 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-fluorophenyl)methyl](3-methylphenyl)amino]carbonyloxy]-1-methyl-, iodide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● I⁻

RN 385367-75-9 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-fluorophenyl)(phenylmethyl)amino]carbonyloxy]-1-methyl-, iodide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● I⁻

RN 385367-76-0 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(cyclohexylmethyl)(2-fluorophenyl)amino]carbonyl]oxy]-1-methyl-, iodide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● I⁻

RN 439907-53-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-52-5

CMF C22 H27 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439907-55-8 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-(4-methyl-3-pentenyl)-3-
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-54-7

CMF C27 H35 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439907-57-0 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenoxypropyl)-3-
 [[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with
 trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439907-56-9
 CMF C30 H35 N2 O3

Absolute stereochemistry.




CM 2

CRN 14477-72-6
 CMF C2 F3 O2



RN 439907-58-1 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-
 1-(3-phenyl-2-propenyl)-, bromide, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 439907-59-2 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-
1-(2-propenyl)-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br⁻

RN 439907-61-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-hydroxyethyl)-3-
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-60-5

CMF C23 H29 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439907-63-8 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-(1-methylethyl)-3-
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439907-62-7
CMF C24 H31 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439907-65-0 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-1-propyl-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439907-64-9
CMF C24 H31 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439907-67-2 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-cyanopropyl)-3-
 [[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with
 trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439907-66-1
 CMF C25 H30 N3 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439907-69-4 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(cyclopropylmethyl)-3-
 [[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with
 trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-68-3
 CMF C25 H31 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439907-71-8 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-ethoxyethyl)-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-70-7

CMF C25 H33 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439907-73-0 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(5-ethoxy-5-oxopentyl)-3-
 [[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with
 trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439907-72-9
 CMF C28 H37 N2 O4

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439907-75-2 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(4-phenylbutyl)-3-
 [[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with
 trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-74-1
 CMF C31 H37 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439907-77-4 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(4-fluorophenoxy)propyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-76-3

CMF C30 H34 F N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439907-79-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-hydroxypropyl)-3-
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-78-5

CMF C24 H31 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439907-81-0 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[4-(acetyloxy)butyl]-3-
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-80-9

CMF C27 H35 N2 O4


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439907-83-2 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[4-oxo-4-(2-thienyl)butyl]-3-
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-82-1

CMF C29 H33 N2 O3 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439907-85-4 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(3-hydroxyphenoxy)propyl]-3-
 [[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with
 trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439907-84-3
 CMF C30 H35 N2 O4

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439907-87-6 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-heptyl-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-86-5
 CMF C28 H39 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439907-89-8 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(phenylmethoxy)ethyl]-3-
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-88-7

CMF C30 H35 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6


CMF C2 F3 O2



RN 439907-90-1 CAPLUS

CN Carbamic acid, (4-fluorophenyl)(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439907-92-3 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-fluorophenyl)(phenylmethyl)amino]carbonyl]oxy]-1-(2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-91-2

CMF C24 H28 F N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439907-94-5 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-fluorophenyl)(phenylmethyl)amino]carbonyl]oxy]-1-(3-phenylpropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439907-93-4
 CMF C30 H34 F N2 O2

Absolute stereochemistry.




CM 2

CRN 14477-72-6
 CMF C2 F3 O2



RN 439907-95-6 CAPLUS
 CN Carbamic acid, (4-methylphenyl)(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439907-97-8 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-methylphenyl)(phenylmethyl)amino]carbonyl]oxy]-1-(2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-96-7

CMF C25 H31 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439907-99-0 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-methylphenyl)(phenylmethyl)amino]carbonyloxy]-1-(3-phenylpropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-98-9

CMF C31 H37 N2 O2


Absolute stereochemistry.



CM 2


CRN 14477-72-6

CMF C2 F3 O2




RN 439908-00-6 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(2-methoxyethoxy)ethyl]-3-
 [[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, bromide, (3R)- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.




RN 439908-01-7 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-phenylethyl)-3-
 [[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, bromide, (3R)- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.



RN 439908-02-8 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-
 1-[3-(2-thienyl)propyl]-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439908-03-9 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-1-(3-phenylpropyl)-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439908-04-0 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-phenoxyethyl)-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439908-06-2 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(3-cyanophenoxy)propyl]-3-
 [[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with
 trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439908-05-1
 CMF C31 H34 N3 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439908-08-4 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(1-naphthalenyloxy)propyl]-3-
 [[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with
 trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-07-3
 CMF C34 H37 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-10-8 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(methylphenylamino)propyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-09-5

CMF C31 H38 N3 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-12-0 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-1-[3-(phenylthio)propyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-11-9

CMF C30 H35 N2 O2 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-14-2 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-(4-oxo-4-phenylbutyl)-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-13-1

CMF C31 H35 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-16-4 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-1-[3-(2,4,6-trimethylphenoxy)propyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-15-3

CMF C33 H41 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-18-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(2-chlorophenoxy)propyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-17-5

CMF C30 H34 Cl N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439908-20-0 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-1-[3-[3-(trifluoromethyl)phenoxy]propyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439908-19-7
CMF C31 H34 F3 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-22-2 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-([1,1'-biphenyl]-4-yloxy)propyl]-3-
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-21-1
CMF C36 H39 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-24-4 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(2,4-difluorophenoxy)propyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-23-3

CMF C30 H33 F2 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-26-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(4-methoxyphenoxy)propyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-25-5

CMF C31 H37 N2 O4


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-28-8 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-1-[3-[(5,6,7,8-tetrahydro-2-naphthalenyl)oxy]propyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-27-7

CMF C34 H41 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-30-2 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(1,3-benzodioxol-5-yloxy)propyl]-3-
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-29-9

CMF C31 H35 N2 O5


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-32-4 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-[2-(aminocarbonyl)phenoxy]propyl]-3-
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-31-3

CMF C31 H36 N3 O4


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-34-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-[3-(dimethylamino)phenoxy]propyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-33-5

CMF C32 H40 N3 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-36-8 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-[4-(acetylamino)phenoxy]propyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-35-7

CMF C32 H38 N3 O4


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-38-0 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-[4-(methoxycarbonyl)phenoxy]propyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with


trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-37-9

CMF C32 H37 N2 O5


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-40-4 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(4-nitrophenoxy)propyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-39-1

CMF C30 H34 N3 O5


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-42-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-[4-(hydroxymethyl)phenoxy]propyl]-3-
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-41-5

CMF C31 H37 N2 O4


Absolute stereochemistry.



CM 2

CRN 14477-72-6


CMF C2 F3 O2



RN 439908-43-7 CAPLUS

CN Carbamic acid, phenyl(phenylmethyl)-, (3S)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439908-45-9 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-1-(3-phenylpropyl)-, bromide, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439908-47-1 CAPLUS

CN Carbamic acid, butylphenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 439908-50-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[butylphenylamino)carbonyl]oxy]-1-methyl-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-49-3

CMF C19 H29 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439908-52-8 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[(butylphenylamino)carbonyl]oxy]-1-(4-methyl-3-pentenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439908-51-7
 CMF C24 H37 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439908-54-0 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[(butylphenylamino)carbonyl]oxy]-1-(3-phenoxypropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-53-9
 CMF C27 H37 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439908-55-1 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-(3-phenyl-2-propenyl)]-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




● Br⁻

RN 439908-56-2 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-(2-propenyl)]-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439908-58-4 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-(2-hydroxyethyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439908-57-3
 CMF C20 H31 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439908-60-8 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-(1-methylethyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-59-5

CMF C21 H33 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-62-0 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[(butylphenylamino) carbonyl]oxy]-1-propyl-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-61-9

CMF C21 H33 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-64-2 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[(butylphenylamino) carbonyl]oxy]-1-(3-cyanopropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-63-1

CMF C22 H32 N3 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-66-4 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[(butylphenylamino) carbonyl]oxy]-1-(cyclopropylmethyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-65-3

CMF C22 H33 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-68-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-(2-ethoxyethyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-67-5

CMF C22 H35 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-70-0 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[(butylphenylamino)carbonyl]oxy]-1-(5-ethoxy-5-oxopentyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-69-7

CMF C25 H39 N2 O4


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-72-2 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[(butylphenylamino)carbonyl]oxy]-1-(3-hydroxypropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-71-1

CMF C21 H33 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-74-4 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-[3-(1H-pyrrol-1-yl)propyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 439908-73-3

CMF C25 H36 N3 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439908-76-6 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[4-(acetyloxy)butyl]-3-
 [[(butylphenylamino)carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid
 (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439908-75-5
 CMF C24 H37 N2 O4

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439908-78-8 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-[4-oxo-
 4-(2-thienyl)butyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)
 (CA INDEX NAME)

CM 1

CRN 439908-77-7
 CMF C26 H35 N2 O3 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-80-2 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[(butylphenylamino) carbonyl]oxy]-1-(4-phenylbutyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-79-9

CMF C28 H39 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439908-82-4 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[(butylphenylamino)carbonyl]oxy]-1-[3-(3-hydroxyphenoxy)propyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)
 (CA INDEX NAME)

CM 1


CRN 439908-81-3
 CMF C27 H37 N2 O4

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439908-84-6 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[(butylphenylamino)carbonyl]oxy]-1-heptyl-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439908-83-5
 CMF C25 H41 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-86-8 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[{(butylphenylamino)carbonyl}oxy]-1-[2-(phenylmethoxy)ethyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)
(CA INDEX NAME)

CM 1


CRN 439908-85-7
CMF C27 H37 N2 O3

Absolute stereochemistry.



CM 2


CRN 14477-72-6
CMF C2 F3 O2



RN 439908-87-9 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[(butylphenylamino)carbonyl]oxy]-1-(2-phenylethyl)-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439908-88-0 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[(butylphenylamino)carbonyl]oxy]-1-[2-(2-methoxyethoxy)ethyl]-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439908-89-1 CAPLUS

CN Carbamic acid, butyl(4-fluorophenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439908-90-4 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[(butylphenylamino)carbonyl]oxy]-1-[3-(4-fluorophenoxy)propyl]-, chloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439908-91-5 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-(2-phenoxyethyl)-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439908-92-6 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-[3-(2-thienyl)propyl]-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439908-93-7 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[butylphenylamino)carbonyl]oxy]-1-(3-phenylpropyl)-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439908-94-8 CAPLUS

CN Carbamic acid, phenyl(2-thienylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439908-95-9 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439908-97-1 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenoxypentyl)-3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439908-96-0
 CMF C28 H33 N2 O3 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439908-99-3 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenylpropyl)-3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-98-2

CMF C28 H33 N2 O2 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-01-0 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenyl-2-propenyl)-3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-00-9

CMF C28 H31 N2 O2 S


Absolute stereochemistry.
Double bond geometry unknown.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-03-2 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(phenylmethoxy)ethyl]-3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-02-1

CMF C28 H33 N2 O3 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-05-4 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(3-hydroxyphenoxy)propyl]-3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-04-3

CMF C28 H33 N2 O4 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-07-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-heptyl-3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-06-5

CMF C26 H37 N2 O2 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6


CMF C2 F3 O2



RN 439909-08-7 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-1-[3-(2-thienyl)propyl]-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439909-09-8 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-phenoxyethyl)-3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439909-10-1 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-1-(2-propenyl)-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439909-11-2 CAPLUS

CN Carbamic acid, phenyl(2-phenylethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439909-12-3 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439909-14-5 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-1-(2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439909-13-4
CMF C25 H31 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-16-7 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenoxypropyl)-3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439909-15-6
CMF C31 H37 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-18-9 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-phenoxyethyl)-3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439909-17-8
CMF C30 H35 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-20-3 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-1-(3-phenylpropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)
 (CA INDEX NAME)

CM 1


CRN 439909-19-0
 CMF C31 H37 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439909-22-5 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-1-(3-phenyl-2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)
 (CA INDEX NAME)

CM 1

CRN 439909-21-4
 CMF C31 H35 N2 O2


Absolute stereochemistry.
 Double bond geometry unknown.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-24-7 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(phenylmethoxy)ethyl]-3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-23-6

CMF C31 H37 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439909-26-9 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(3-hydroxyphenoxy)propyl]-3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid
 (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439909-25-8
 CMF C31 H37 N2 O4

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439909-29-2 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-heptyl-3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid
 (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-28-1
 CMF C29 H41 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-32-7 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-1-[3-(2-thienyl)propyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-31-6

CMF C29 H35 N2 O2 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6


CMF C2 F3 O2



RN 439909-34-9 CAPLUS

CN Carbamic acid, pentylphenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 439909-36-1 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[(pentylphenylamino)carbonyl]oxy]-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br⁻

RN 439909-39-4 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[(pentylphenylamino)carbonyl]oxy]-1-(3-phenoxypropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-38-3

CMF C28 H39 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-41-8 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(pentylphenylamino)carbonyl]oxy]-1-(2-phenoxyethyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-40-7

CMF C27 H37 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-43-0 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[(pentylphenylamino)carbonyl]oxy]-1-(3-phenylpropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-42-9

CMF C28 H39 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-45-2 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[(pentylphenylamino)carbonyl]oxy]-1-(3-phenyl-2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 439909-44-1

CMF C28 H37 N2 O2

Absolute stereochemistry.


Double bond geometry unknown.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-47-4 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[(pentylphenylamino)carbonyl]oxy]-1-[2-(phenylmethoxy)ethyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 439909-46-3

CMF C28 H39 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439909-49-6 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(3-hydroxyphenoxy)propyl]-3-
 [[(pentylphenylamino)carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid
 (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439909-48-5
 CMF C28 H39 N2 O4

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439909-51-0 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-heptyl-3-[[pentylphenylamino]carbonyl]oxy
]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-50-9
 CMF C26 H43 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-53-2 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[(pentylphenylamino)carbonyl]oxy]-1-[3-(2-thienyl)propyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-52-1

CMF C26 H37 N2 O2 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6


CMF C2 F3 O2



RN 439909-54-3 CAPLUS

CN Carbamic acid, 4-pentenylphenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439909-56-5 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[4-pentenylphenylamino)carbonyl]oxy]-1-(2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-55-4

CMF C22 H31 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-58-7 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[4-pentenylphenylamino)carbonyl]oxy]-1-

(3-phenoxypropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439909-57-6
CMF C28 H37 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-60-1 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[4-(3-allylphenylamino)carbonyloxy]-1-(2-phenoxyethyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439909-59-8
CMF C27 H35 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-62-3 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[4-pentenylphenylamino)carbonyl]oxy]-1-(3-phenylpropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439909-61-2
CMF C28 H37 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-64-5 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[4-pentenylphenylamino)carbonyl]oxy]-1-(3-phenyl-2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-63-4
CMF C28 H35 N2 O2


Absolute stereochemistry.
Double bond geometry unknown.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-66-7 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[4-pentenylphenylamino)carbonyl]oxy]-1-[2-(phenylmethoxy)ethyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-65-6

CMF C28 H37 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439909-68-9 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(3-hydroxyphenoxy)propyl]-3-[[4-pentenylphenylamino)carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439909-67-8
 CMF C28 H37 N2 O4

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439909-70-3 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-heptyl-3-[[4-pentenylphenylamino)carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-69-0
 CMF C26 H41 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-72-5 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[[4-pentenylphenylamino)carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-71-4

CMF C20 H29 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439909-75-8 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[4-pentenylphenylamino)carbonyl]oxy]-1-[3-(2-thienyl)propyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)
 (CA INDEX NAME)

CM 1


CRN 439909-74-7
 CMF C26 H35 N2 O2 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439909-79-2 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-1-(2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)
 (CA INDEX NAME)

CM 1

CRN 439909-78-1
 CMF C22 H27 N2 O2 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-81-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenoxypropyl)-3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-80-5

CMF C28 H33 N2 O3 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439909-83-8 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenylpropyl)-3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439909-82-7
 CMF C28 H33 N2 O2 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439909-85-0 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenyl-2-propenyl)-3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-84-9
 CMF C28 H31 N2 O2 S


Absolute stereochemistry.
 Double bond geometry unknown.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-87-2 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(phenylmethoxy)ethyl]-3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-86-1

CMF C28 H33 N2 O3 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439909-89-4 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(3-hydroxyphenoxy)propyl]-3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439909-88-3
 CMF C28 H33 N2 O4 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439909-91-8 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-heptyl-3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-90-7
 CMF C26 H37 N2 O2 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-93-0 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-92-9

CMF C20 H25 N2 O2 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6


CMF C2 F3 O2



RN 439909-94-1 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-1-[3-(2-thienyl)propyl]-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439909-95-2 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-phenoxyethyl)-3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439910-19-7 CAPLUS

CN Carbamic acid, cyclopentyl(2-thienylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439910-21-1 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[cyclopentyl(2-thienylmethyl)amino]carbonyl]oxy]-1-(2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439910-20-0

CMF C21 H31 N2 O2 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439910-25-5 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[cyclopentyl(2-thienylmethyl)amino]carbonyl]oxy]-1-(3-phenylpropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439910-24-4

CMF C27 H37 N2 O2 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6


CMF C2 F3 O2



RN 439910-27-7 CAPLUS

CN Carbamic acid, (2-furanylmethyl)phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439910-30-2 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-furanylmethyl)phenylamino]carbonyloxy]-1-(2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439910-29-9

CMF C22 H27 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439910-33-5 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-furanylmethyl)phenylamino]carbonyl]oxy]-1-(3-phenylpropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 439910-32-4

CMF C28 H33 N2 O3


Absolute stereochemistry.



CM 2


CRN 14477-72-6

CMF C2 F3 O2



RN 439910-45-9 CAPLUS

CN Carbamic acid, phenyl(phenylmethyl)-, 1-azabicyclo[2.2.2]oct-4-yl ester (9CI) (CA INDEX NAME)




RN 637744-43-5 CAPLUS

CN Carbamic acid, phenyl(phenylmethyl)-, 1-azabicyclo[2.2.1]hept-4-yl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 439910-43-7


CMF C20 H22 N2 O2



CM 2

CRN 64-18-6


CMF C H2 O2



RN 637744-64-0 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(3-methylphenyl)[(2,4,5-trifluorophenyl)methyl]amino]carbonyl]oxy]-1-(2-phenoxyethyl)-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 637744-67-3 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(3-fluorophenyl)[(3-fluorophenyl)methyl]amino]carbonyl]oxy]-1-(2-phenoxyethyl)-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 637744-68-4 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(3-fluorophenyl)[(3-fluorophenyl)methyl]amino]carbonyl]oxy]-1-(3-phenylpropyl)-, bromide, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● Br⁻

RN 637744-69-5 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(3-methylphenyl)[(2,4,5-trifluorophenyl)methyl]amino]carbonyl]oxy]-1-(3-phenylpropyl)-, bromide, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● Br⁻

RN 637744-70-8 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino]carbonyl]oxy]-1-(2-phenoxyethyl)-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 637744-71-9 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(cyclohexylmethyl)(2-fluorophenyl)amino]carbonyl]oxy]-1-(2-phenoxyethyl)-, bromide, (3R)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 637744-72-0 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(cyclohexylmethyl)(2-fluorophenyl)amino]carbonyl]oxy]-1-(3-phenylpropyl)-, bromide, (3R)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 637744-76-4 CAPLUS
 CN Carbamic acid, [(5-bromo-2-thienyl)methyl](2,4,5-trifluorophenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 637744-75-3
 CMF C19 H18 Br F3 N2 O2 S

Absolute stereochemistry.




CM 2

CRN 64-18-6
 CMF C H2 O2

O=CH-OH

RN 637744-78-6 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-fluoro-2-methylphenyl)[(3-methyl-2-thienyl)methyl]amino]carbonyl]oxy]-1-(2-phenoxyethyl)-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 637744-80-0 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(3-fluoro-4-methoxyphenyl)(3-thienylmethyl)amino]carbonyl]oxy]-1-(3-phenyl-2-propenyl)-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



● Br⁻

RN 637744-84-4 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(pentylphenylamino)carbonyl]oxy]-1-(2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 637744-83-3

CMF C22 H33 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 637744-85-5 CAPLUS

CN Carbamic acid, phenyl(phenylmethyl)-, 1-azabicyclo[2.2.2]oct-4-yl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 439910-45-9


CMF C21 H24 N2 O2



CM 2

CRN 64-18-6


CMF C H2 O2



RN 637744-89-9 CAPLUS

CN Carbamic acid, butyl(2,5-difluorophenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 637744-90-2 CAPLUS

CN Carbamic acid, (2,6-difluorophenyl)-4-pentenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 637744-91-3 CAPLUS

CN Carbamic acid, cyclopentyl[(4,5-dimethyl-2-thienyl)methyl]-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 637744-94-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(5-bromo-2-thienyl)methyl](2,4,5-trifluorophenyl)amino]carbonyloxy]-1-(3-phenoxypropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 637744-93-5

CMF C28 H29 Br F3 N2 O3 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 637744-97-9 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-fluoro-2-methylphenyl)[(3-methyl-2-thienyl)methyl]amino]carbonyl]oxy]-1-(2-phenoxyethyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 637744-96-8

CMF C29 H34 F N2 O3 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 637744-99-1 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(3-fluoro-4-methoxyphenyl) (3-thienylmethyl)amino]carbonyl]oxy]-1-(3-phenyl-2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 637744-98-0
 CMF C29 H32 F N2 O3 S

Absolute stereochemistry.
 Double bond geometry unknown.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 637745-13-2 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[butyl(2,5-difluorophenyl)amino]carbonyl]oxy]-1-heptyl-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 637745-12-1
 CMF C25 H39 F2 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 637745-15-4 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-cyanopropyl)-3-[[[(2,6-difluorophenyl)-4-pentenylamino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 637745-14-3

CMF C23 H30 F2 N3 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 637745-17-6 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[cyclopentyl[(4,5-dimethyl-2-thienyl)methyl]amino]carbonyl]oxy]-1-methyl-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 637745-16-5
 CMF C21 H33 N2 O2 S

Absolute stereochemistry.




CM 2

CRN 14477-72-6
 CMF C2 F3 O2



RN 637745-18-7 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino]carbonyl]oxy]-1-(3-phenylpropyl)-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



ACCESSION NUMBER: 2003:511328 CAPLUS

DOCUMENT NUMBER: 139:85531

TITLE: Preparation of 1-alkyl-1-azoniabicyclo[2.2.2]octane carbamate derivatives

INVENTOR(S): Catena Ruiz, Juan Lorenzo; Farrerons Gallemi, Carles; Fernandez Serrat, Anna; Miquel Bono, Ignacio Jose; Balsa Lopez, Dolors; Lagunas Arnal, Carmen; Salcedo Roca, Carolina; Toledo Mesa, Natividad; Fernandez Garcia, Andres

PATENT ASSIGNEE(S): Laboratorios S.A.L.V.A.T., S.A., Spain

SOURCE: PCT Int. Appl., 56 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003053966	A2	20030703	WO 2002-EP14470	20021218
WO 2003053966	A3	20031113		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2470956	C	20030703	CA 2002-2470956	20021218
AU 2002361158	A1	20030709	AU 2002-361158	20021218
EP 1461336	A2	20040929	EP 2002-796673	20021218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002015348	A	20041116	BR 2002-15348	20021218
HU 2005000107	A2	20050530	HU 2005-107	20021218
JP 2005516954	T	20050609	JP 2003-5546821	20021218
CN 1832948	A	20060913	CN 2002-827836	20021218
MX 2004PA06206	A	20041206	MX 2004-PA6206	20040621
NO 2004003064	A	20040917	NO 2004-3064	20040719
US 2005043349	A1	20050224	US 2004-499130	20041012
PRIORITY APPLN. INFO.:			ES 2002-43	A 20011220
			WO 2002-EP14470	W 20021218
OTHER SOURCE(S):			MARPAT 139:85531	
GI				



I

AB The title compds. I (R1, R2 and R3 = H, OH, NO2, SH, CN, F, Cl, Br, I, COOH, CONH2, (C1-C4)-alkoxycarbonyl, (C1-C4)-alkylsulfanyl,

(C1-C4)-alkylsulfinyl, (C1-C4)-alkylsulfonyl, (C1-C4)-alkoxyl optionally substituted with one or several F, and (C1-C4)-alkyl optionally substituted with one or several F or OH; R4 = cycloalkyl, Ph, heteroaryl or a bicyclic ring system; R5 = cycloalkyl, (C5-C10)-alkyl, a substituted (C1-C10)-alkyl; and X- = physiologically acceptable anion) were prepared. I is a selective muscarinic M3 receptor antagonists vs. M2 receptor and may be used for the treatment of urinary incontinence (particularly, the one caused by overactive bladder), irritable bowel syndrome, and respiratory disorders (particularly, chronic obstructive pulmonary disease, chronic bronchitis, asthma, emphysema, and rhinitis), as well as in ophthalmic interventions. Thus, (R)-benzylphenylcarbamate acid 1-azabicyclo[2.2.2]oct-3-yl ester hydrochloride was treated with bromocyclopropane to give (R)-I (R1, R2, R3 = H, R4 = Ph, R5 = cyclopropylmethyl, X = Br). The M2/M3 ratio of (R)-I (R1, R2, R3 = H, R4 = 4-FC6H4, R5 = 3-phenoxypropyl, X = Br) was 80.

IT 552830-52-1P 552830-53-2P 552830-54-3P
 552830-55-4P 552830-56-5P 552830-57-6P
 552830-58-7P 552830-59-8P 552830-60-1P
 552830-61-2P 552830-62-3P 552830-63-4P
 552830-64-5P 552830-65-6P 552830-66-7P
 552830-67-8P 552830-68-9P 552830-69-0P
 552830-70-3P 552830-71-4P 552830-72-5P
 552830-73-6P 552830-74-7P 552830-75-8P
 552830-76-9P 552830-77-0P 552830-78-1P
 552830-79-2P 552830-80-5P 552830-81-6P
 552830-82-7P 552830-83-8P 552830-84-9P
 552830-85-0P 552830-86-1P 552830-87-2P
 552830-88-3P 552830-89-4P 552830-90-7P
 552830-91-8P 552830-92-9P 552830-93-0P
 552830-94-1P 552830-95-2P 552830-96-3P
 552830-97-4P 552830-98-5P 552830-99-6P
 552831-00-2P 552831-01-3P 552831-02-4P
 552831-03-5P 552831-04-6P 552831-05-7P
 552831-06-8P 552831-07-9P 552831-08-0P
 552831-09-1P 552831-10-4P 552831-11-5P
 552831-12-6P 552831-13-7P 552831-14-8P
 552831-15-9P 552831-16-0P 552831-17-1P
 552831-18-2P 552831-19-3P 552831-20-6P
 552831-21-7P 552831-22-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 1-alkyl-1-azoniabicyclo[2.2.2]octane carbamate derivs. as muscarinic receptor antagonists)

RN 552830-52-1 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-cyclopropyl-3-
 [[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, bromide, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● Br⁻

RN 552830-53-2 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[(2-chlorophenyl)methyl]-3-
 [[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, chloride, (3R)- (9CI) (CA
 INDEX NAME)


Absolute stereochemistry.



● Cl⁻

RN 552830-54-3 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[[[5-(methylthio)-1H-1,2,4-triazol-3-
 yl]thio]methyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, chloride,
 (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Cl⁻

RN 552830-55-4 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-ethoxy-2-oxoethyl)-3-
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, bromide, (3R)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 552830-56-5 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(2,3-dihydro-5-benzofuranyl)ethyl]-3-
[[[(3-methylphenyl)(phenylmethyl)amino]carbonyl]oxy]-, bromide, (3R)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



● Br⁻

RN 552830-57-6 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(2,3-dihydro-5-benzofuranyl)ethyl]-3-
 [[[(3-fluorophenyl)(phenylmethyl)amino]carbonyl]oxy]-, bromide, (3R)-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● Br⁻

RN 552830-58-7 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-fluorophenyl)methyl]phenylamino]car
 bonyl]oxy]-1-[2-(3-methylphenyl)ethyl]-, bromide, (3R)- (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.



RN 552830-59-8 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(4-ethoxyphenyl)ethyl]-3-[[[(4-fluorophenyl)methyl]phenylamino]carbonyloxy]-, bromide, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-60-1 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-fluorophenyl)methyl]phenylamino]carbonyloxy]-1-[2-(4-nitrophenyl)ethyl]-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 552830-61-2 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-[(2,4-difluorophenyl)thio]ethyl]-3-[[[(4-fluorophenyl)methyl]phenylamino]carbonyloxy]-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 552830-62-3 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-fluorophenyl)methyl]phenylamino]carbonyloxy]-1-(3-phenoxypropyl)-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 552830-63-4 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-(cyclobutylmethyl)-3-[[[(4-fluorophenyl)methyl] (3-methylphenyl)amino]carbonyloxy]-, bromide, (3R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 552830-64-5 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(3,4-dimethoxyphenyl)ethyl]-3-[[[(2-fluorophenyl) [(4-fluorophenyl)methyl]amino]carbonyloxy]-, bromide, (3R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-65-6 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-1-[2-(4-methoxyphenyl)-2-oxoethyl]-, bromide; (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-66-7 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-1-[2-(1H-pyrrol-2-yl)ethyl]-, bromide; (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-67-8 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-, bromide, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-68-9 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-1-[2-(3-methoxyphenoxy)-2-oxoethyl]-, bromide, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-69-0 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(cyclopentylamino)-2-oxoethyl]-3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyloxy]-, bromide, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-70-3 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-[(2-fluorophenyl)amino]-2-oxoethyl]-3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyloxy]-, bromide, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-71-4 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-[[4-(acetamino)phenyl]thio]ethyl]-3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-, bromide, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-72-5 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-[(2,3-dimethylphenyl)thio]ethyl]-3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-, bromide, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-73-6 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-1-[2-[(1-methyl-1H-imidazol-2-yl)thio]ethyl]-, chloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-74-7 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-1-[2-[(2-methoxyphenyl)sulfinyl]ethyl]-, chloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-75-8 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-1-[2-[(2-methoxyphenyl)thio]-2-oxoethyl]-, bromide, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-76-9 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(benzoyloxy)ethyl]-3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 552830-77-0 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(benzoylamino)ethyl]-3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-, chloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Cl⁻

RN 552830-78-1 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 552830-79-2 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-1-[2-[(phenylsulfonyl)amino]ethyl]-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 552830-80-5 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(2-cyanophenoxy)propyl]-3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-, bromide, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-81-6 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-1-[3-(3-nitrophenoxy)propyl]-, chloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-82-7 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-1-[3-[(5-methyl-2-pyrimidinyl)oxy]propyl]-, bromide, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-83-8 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-1-[3-(2-pyridinylthio)propyl]-, bromide, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-84-9 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(2-benzoxazolylthio)propyl]-3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-, chloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● Cl⁻

RN 552830-85-0 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-1-[3-[(2-fluorophenyl)sulfonyl]propyl]-, chloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● Cl⁻

RN 552830-86-1 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-[acetyl(4-chlorophenyl)amino]propyl]-3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-, chloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Cl⁻

RN 552830-87-2 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-fluorophenyl) [(4-fluorophenyl)methyl]amino]carbonyl]oxy]-1-[3-[(4-fluorophenyl) [(phenylmethoxy)carbonyl]amino]propyl]-, chloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Cl⁻

RN 552830-88-3 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-fluorophenyl) [(4-fluorophenyl)methyl]amino]carbonyl]oxy]-1-[3-oxo-3-(phenylamino)propyl]-, chloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Cl⁻

RN 552830-89-4 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(benzoyloxy)propyl]-3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyloxy]-, bromide, (3R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 552830-90-7 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-[[4-(acetamino)phenyl]thio]ethyl]-3-[[[(3-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyloxy]-, bromide, (3R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-91-8 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(3,4-difluorophenyl)methyl]phenylamino]carbonyloxy]-1-[3-(4-fluorophenoxy)-2-hydroxypropyl]-, hydroxide, (3R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-92-9 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(3-chloro-5-fluorophenyl)ethyl]-3-[[[(3,4-difluorophenyl)methyl](2-fluorophenyl)amino]carbonyloxy]-, chloride, (3R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-93-0 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-cyclohexylethyl)-3-[[[(3,4-difluorophenyl)methyl](2-fluorophenyl)amino]carbonyl]oxy]-, chloride, (3R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-94-1 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(3,4-difluorophenyl)methyl](2-fluorophenyl)amino]carbonyl]oxy]-1-[2-(phenylsulfonyl)ethyl]-, chloride, (3R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Cl⁻

RN 552830-95-2 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(3,4-difluorophenyl)methyl](3-methylphenyl)amino]carbonyl]oxy]-1-[2-(phenylthio)ethyl]-, chloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Cl⁻

RN 552830-96-3 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(3,4-difluorophenyl)methyl](3-methylphenyl)amino]carbonyl]oxy]-1-[3-[(4-fluorophenyl)thio]propyl]-, chloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 552830-97-4 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[[(3,4-difluorophenyl)methyl] (3-fluorophenyl)amino]carbonyloxy]-1-(2-phenoxyethyl)-, bromide, (3R)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 552830-98-5 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(3,4-difluorophenyl)methyl] (3-fluorophenyl)amino]carbonyloxy]-1-(3-phenylpropyl)-, bromide, (3R)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 552830-99-6 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-(cyclopropylmethyl)-3-[[[(2-fluorophenyl) [(3,4,5-trifluorophenyl)methyl]amino]carbonyloxy]-, bromide, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● Br⁻

RN 552831-00-2 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino]carbonyl]oxy]-1-(phenylmethyl)-, bromide, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● Br⁻

RN 552831-01-3 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino]carbonyl]oxy]-1-[2-(phenylthio)ethyl]-, chloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Cl⁻

RN 552831-02-4 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino]carbonyl]oxy]-1-(3-phenoxypropyl)-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





● Br⁻

RN 552831-03-5 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(3,4-difluorophenoxy)propyl]-3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino]carbonyl]oxy]-, chloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 552831-04-6 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(3-methylphenyl)(2-thienylmethyl)amino]carbonyl]oxy]-1-(2-oxo-2-phenylethyl)-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 552831-05-7 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(3-methylphenyl)(2-thienylmethyl)amino]carbonyl]oxy]-1-(3-phenylpropyl)-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 552831-06-8 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-fluorophenyl)(2-thienylmethyl)amino]carbonyl]oxy]-1-(phenylmethyl)-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 552831-07-9 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-(cyclobutylmethyl)-3-[[[(3-fluorophenyl)(2-thienylmethyl)amino]carbonyl]oxy]-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 552831-08-0 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(3-methyl-2-thienyl)methyl]phenylamino]carbonyl]oxy]-1-(2-phenoxyethyl)-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 552831-09-1 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-bromo-2-thienyl)methyl]phenylamino]carbonyl]oxy]-1-(cyclopropylmethyl)-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 552831-10-4 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-bromo-2-thienyl)methyl]phenylamino]carbonyl]oxy]-1-[(phenylthio)methyl]-, chloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Cl⁻

RN 552831-11-5 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(2,3-dihydro-5-benzofuranyl)ethyl]-3-[[[(5-methyl-2-thienyl)methyl]phenylamino]carbonyl]oxy]-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 552831-12-6 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(5-chloro-2-thienyl)methyl](2-fluorophenyl)amino]carbonyl]oxy]-1-(2-phenoxyethyl)-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 552831-13-7 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(5-bromo-2-thienyl)methyl]phenylamino]carbonyl]oxy]-1-(cyclopropylmethyl)-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 552831-14-8 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(5-bromo-2-thienyl)methyl]phenylamino]carbonyl]oxy]-1-[2-(phenylthio)ethyl]-, chloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Cl⁻

RN 552831-15-9 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(5-bromo-2-thienyl)methyl](3-methylphenyl)amino]carbonyloxy]-1-[(phenylthio)methyl]-, chloride, (3R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Cl⁻

RN 552831-16-0 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(5-bromo-2-thienyl)methyl](4-fluorophenyl)amino]carbonyloxy]-1-(cyclopropylmethyl)-, bromide, (3R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 552831-17-1 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[[(5-bromo-2-thienyl)methyl](4-fluorophenyl)amino]carbonyl]oxy]-1-(2-oxo-2-phenylethyl)-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 552831-18-2 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[[(5-bromo-2-thienyl)methyl](4-fluorophenyl)amino]carbonyl]oxy]-1-(3-phenylpropyl)-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 552831-19-3 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-(cyclobutylmethyl)-3-[[[(3-fluorophenyl)(3-thienylmethyl)amino]carbonyl]oxy]-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 552831-20-6 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(3-fluorophenyl)(3-thienylmethyl)amino]carbonyl]oxy]-1-(2-oxo-2-phenylethyl)-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 552831-21-7 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(cyclohexylmethyl)phenylamino]carbonyl]oxy]-1-(2-oxo-2-phenylethyl)-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 552831-22-8 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(cyclohexylmethyl)phenylamino]carbonyl]oxy]-1-(3-phenoxypropyl)-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br⁻


IT 552860-70-5 552860-71-6 552860-72-7
 552860-73-8 552860-75-0 552860-76-1
 552860-77-2 552860-78-3 552860-79-4
 552860-80-7 552860-81-8 552860-82-9
 552860-83-0

RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of 1-alkyl-1-azoniabicyclo[2.2.2]octane carbamate derivs. as
 muscarinic receptor antagonists)

RN 552860-70-5 CAPLUS

CN Carbamic acid, (3-methylphenyl)(phenylmethyl)-, (3R)-1-
 azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 552860-71-6 CAPLUS

CN Carbamic acid, (3-fluorophenyl)(phenylmethyl)-, (3R)-1-
 azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 552860-72-7 CAPLUS
 CN Carbamic acid, [(4-fluorophenyl)methyl]phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 552860-73-8 CAPLUS
 CN Carbamic acid, [(4-fluorophenyl)methyl](3-methylphenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 552860-75-0 CAPLUS

CN Carbamic acid, (2-fluorophenyl)[(4-fluorophenyl)methyl]-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX
NAME)

Absolute stereochemistry.




● HCl

RN 552860-76-1 CAPLUS

CN Carbamic acid, (3-fluorophenyl)[(4-fluorophenyl)methyl]-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX
NAME)

Absolute stereochemistry.




● HCl

RN 552860-77-2 CAPLUS

CN Carbamic acid, [(3,4-difluorophenyl)methyl]phenyl-, (3R)-1-
azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 552860-78-3 CAPLUS

CN Carbamic acid, [(3,4-difluorophenyl)methyl](3-methylphenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 552860-79-4 CAPLUS

CN Carbamic acid, [(3,4-difluorophenyl)methyl](2-fluorophenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 552860-80-7 CAPLUS

CN Carbamic acid, [(3,4-difluorophenyl)methyl](3-fluorophenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 552860-81-8 CAPLUS

CN Carbamic acid, (2-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 552860-82-9 CAPLUS

CN Carbamic acid, (3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 552860-83-0 CAPLUS

CN Carbamic acid, (cyclohexylmethyl)phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 385367-79-3P 552831-24-0P 552831-25-1P
 552831-26-2P 552831-27-3P 552831-28-4P
 552831-29-5P 552831-30-8P 552831-31-9P
 552831-32-0P 552831-33-1P 552831-34-2P
 552831-35-3P 552831-36-4P 552831-37-5P
 552831-38-6P 552831-39-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 1-alkyl-1-azoniabicyclo[2.2.2]octane carbamate derivs. as muscarinic receptor antagonists)

RN 385367-79-3 CAPLUS

CN Carbamic acid, phenyl(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● HCl

RN 552831-24-0 CAPLUS

CN Carbamic acid, (3-methylphenyl)(2-thienylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 552831-25-1 CAPLUS

CN Carbamic acid, (2-fluorophenyl)(2-thienylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 552831-26-2 CAPLUS

CN Carbamic acid, (3-fluorophenyl)(2-thienylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 552831-27-3 CAPLUS

CN Carbamic acid, [(4-methyl-2-thienyl)methyl]phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 552831-28-4 CAPLUS
CN Carbamic acid, [(4-bromo-2-thienyl)methyl]phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 552831-29-5 CAPLUS
CN Carbamic acid, [(5-methyl-2-thienyl)methyl]phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 552831-30-8 CAPLUS
CN Carbamic acid, [(5-chloro-2-thienyl)methyl](2-fluorophenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 552831-31-9 CAPLUS

CN Carbamic acid, [(5-bromo-2-thienyl)methyl]phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 552831-32-0 CAPLUS

CN Carbamic acid, [(5-bromo-2-thienyl)methyl](3-methylphenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 552831-33-1 CAPLUS

CN Carbamic acid, (3-fluorophenyl)(3-thienylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 552831-34-2 CAPLUS

CN Carbamic acid, (2-fluorophenyl)[(3-methyl-2-thienyl)methyl]-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 552831-35-3 CAPLUS

CN Carbamic acid, (2-fluorophenyl)[(5-methyl-2-thienyl)methyl]-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 552831-36-4 CAPLUS
 CN Carbamic acid, [(5-chloro-2-thienyl)methyl](3-fluorophenyl)-,
 (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.



● HCl

RN 552831-37-5 CAPLUS
 CN Carbamic acid, [(5-ethyl-2-thienyl)methyl](3-methylphenyl)-,
 (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.




● HCl

RN 552831-38-6 CAPLUS

CN Carbamic acid, phenyl(3-thienylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 552831-39-7 CAPLUS

CN Carbamic acid, (3-methylphenyl)(3-thienylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.




● HCl

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2002:504786 CAPLUS
 DOCUMENT NUMBER: 137:79107
 TITLE: Preparation of quinuclidine carbamate derivatives as
 M3 antagonists
 INVENTOR(S): Buil Albero, Maria Antonia; Fernandez Forner, Maria
 Dolors; Prat Quinones, Maria
 PATENT ASSIGNEE(S): Almirall Prodesfarma, S.A., Spain
 SOURCE: PCT Int. Appl., 68 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002051841	A1	20020704	WO 2001-EP15169	20011220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2441896	A1	20020704	CA 2001-2441896	20011220
AU 2002228015	A1	20020708	AU 2002-228015	20011220
AU 2002228015	B2	20070823		
EP 1345937	A1	20030924	EP 2001-989610	20011220
EP 1345937	B1	20050928		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001016450	A	20030930	BR 2001-16450	20011220
EE 200300295	A	20031015	EE 2003-295	20011220
HU 2003003529	A2	20040128	HU 2003-3529	20011220
CN 1492868	A	20040428	CN 2001-822829	20011220
JP 2004530641	T	20041007	JP 2002-552936	20011220
NZ 526580	A	20050429	NZ 2001-526580	20011220
AT 305468	T	20051015	AT 2001-989610	20011220
ES 2248409	T3	20060316	ES 2001-1989610	20011220
RU 2296762	C2	20070410	RU 2003-122341	20011220
US 2004266816	A1	20041230	US 2002-193622	20020710
US 7208501	B2	20070424		
US 2004242629	A1	20041202	US 2003-404395	20030331
IN 2003DN00939	A	20070105	IN 2003-DN939	20030617
MX 2003PA05583	A	20040505	MX 2003-PA5583	20030619
BG 107930	A	20040831	BG 2003-107930	20030619
ZA 2003004769	A	20040920	ZA 2003-4769	20030619
NO 2003002889	A	20030808	NO 2003-2889	20030623
HK 1055120	A1	20060106	HK 2003-107423	20031015
PRIORITY APPLN. INFO.:				
ES 2000-3084 A 20001222				
WO 2001-EP15169 W 20011220				
US 2002-193622 A1 20020710				
OTHER SOURCE(S): MARPAT 137:79107				
GI				



I



II

AB The title compds. I (R1 = unsubstituted, halo substituted, alkyl substituted, or cyano substituted Ph, 2-thienylmethyl, 2-thienyl, 2-furylmethyl, 2-furyl, 3-thienylmethyl, 3-thienyl, 3-furylmethyl, 3-furyl; R2 = benzyl, phenethyl, 2-furylmethyl, 3-furylmethyl, 2-thienylmethyl or 3-thienylmethyl group or a straight or branched alkyl group having 3 or 8 carbon atoms, an alkenyl group having 3 to 8 carbons atoms, or a cycloalkyl group of 3 to 6 carbon atoms; p = 1 or 2; the substitution in the azoniabicyclic ring may be in the 2, 3 or 4 position including all possible configurations of the asym. carbons) and their pharmaceutically acceptable salts II (A = CH2, R3C:CH, CH:CR3, CO, O, S, SO, SO2, NR3, CR3R4; B = O2CR3, CO2R3, cyano, etc.; R3, R4 = H, alkyl, R3R4 = alicyclic ring; m = 0-8, n = 0-4) were prepared as M3 antagonists. Thus, (R)-3-hydroxy-1-azabicyclo[2.2.2]octane was treated with phenylbutylcarbonyl chloride to give the corresponding carbamate. The binding to receptor M3 receptor IC50 of benzylphenylcarbamic acid (R)-1-azabicyclo[2.2.2]octyl-3-yl ester was 5.0 nM.


IT 385367-13-5P 439907-90-1P 439907-95-6P
439908-47-1P 439908-89-1P 439908-94-8P
439909-11-2P 439909-34-9P 439909-54-3P
439909-77-0P 439910-19-7P 439910-27-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of quinuclidine carbamate derivs. as M3 antagonists)

RN 385367-13-5 CAPLUS

CN Carbamic acid, phenyl(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 439907-90-1 CAPLUS

CN Carbamic acid, (4-fluorophenyl)(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439907-95-6 CAPLUS

CN Carbamic acid, (4-methylphenyl)(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439908-47-1 CAPLUS

CN Carbamic acid, butylphenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439908-89-1 CAPLUS

CN Carbamic acid, butyl(4-fluorophenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439908-94-8 CAPLUS

CN Carbamic acid, phenyl(2-thienylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439909-11-2 CAPLUS

CN Carbamic acid, phenyl(2-phenylethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439909-34-9 CAPLUS

CN Carbamic acid, pentylphenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439909-54-3 CAPLUS

CN Carbamic acid, 4-pentenylphenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439909-77-0 CAPLUS

CN Carbamic acid, phenyl(3-thienylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439910-19-7 CAPLUS

CN Carbamic acid, cyclopentyl(2-thienylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439910-27-7 CAPLUS

CN Carbamic acid, (2-furanylmethyl)phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 439907-53-6P 439907-55-8P 439907-57-0P
 439907-58-1P 439907-59-2P 439907-61-6P
 439907-63-8P 439907-65-0P 439907-67-2P
 439907-69-4P 439907-71-8P 439907-73-0P
 439907-75-2P 439907-77-4P 439907-79-6P
 439907-81-0P 439907-83-2P 439907-85-4P
 439907-87-6P 439907-89-8P 439907-92-3P
 439907-94-5P 439907-97-8P 439907-99-0P
 439908-00-6P 439908-01-7P 439908-02-8P
 439908-03-9P 439908-04-0P 439908-06-2P
 439908-08-4P 439908-10-8P 439908-12-0P
 439908-14-2P 439908-16-4P 439908-18-6P
 439908-20-0P 439908-22-2P 439908-24-4P
 439908-26-6P 439908-28-8P 439908-30-2P
 439908-32-4P 439908-34-6P 439908-36-8P
 439908-38-0P 439908-40-4P 439908-42-6P
 439908-45-9P 439908-50-6P 439908-52-8P

439908-54-0P 439908-55-1P 439908-56-2P
 439908-58-4P 439908-60-8P 439908-62-0P
 439908-64-2P 439908-66-4P 439908-68-6P
 439908-70-0P 439908-72-2P 439908-74-4P
 439908-76-6P 439908-78-8P 439908-80-2P
 439908-82-4P 439908-84-6P 439908-86-8P
 439908-87-9P 439908-88-0P 439908-90-4P
 439908-91-5P 439908-92-6P 439908-93-7P
 439908-95-9P 439908-97-1P 439908-99-3P
 439909-01-0P 439909-03-2P 439909-05-4P
 439909-07-6P 439909-08-7P 439909-09-8P
 439909-10-1P 439909-12-3P 439909-14-5P
 439909-16-7P 439909-18-9P 439909-20-3P
 439909-22-5P 439909-24-7P 439909-26-9P
 439909-29-2P 439909-32-7P 439909-36-1P
 439909-37-2P 439909-39-4P 439909-41-8P
 439909-43-0P 439909-45-2P 439909-47-4P
 439909-49-6P 439909-51-0P 439909-53-2P
 439909-56-5P 439909-58-7P 439909-60-1P
 439909-62-3P 439909-64-5P 439909-66-7P
 439909-68-9P 439909-70-3P 439909-72-5P
 439909-75-8P 439909-79-2P 439909-81-6P
 439909-83-8P 439909-85-0P 439909-87-2P
 439909-89-4P 439909-91-8P 439909-93-0P
 439909-94-1P 439909-95-2P 439910-21-1P
 439910-25-5P 439910-30-2P 439910-33-5P
 439910-43-7P 439910-45-9P 439910-49-3P
 439910-50-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinuclidine carbamate derivs. as M3 antagonists)

RN 439907-53-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-52-5

CMF C22 H27 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439907-55-8 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(4-methyl-3-pentenyl)-3-
 [[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with
 trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439907-54-7
 CMF C27 H35 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439907-57-0 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenoxypropyl)-3-
 [[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with
 trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-56-9
 CMF C30 H35 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439907-58-1 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-1-(3-phenyl-2-propenyl)-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




● Br⁻

RN 439907-59-2 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-1-(2-propenyl)-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439907-61-6 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-hydroxyethyl)-3-
 [[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with
 trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439907-60-5
 CMF C23 H29 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439907-63-8 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(1-methylethyl)-3-
 [[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with
 trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-62-7

CMF C24 H31 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439907-65-0 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-1-propyl-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-64-9

CMF C24 H31 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439907-67-2 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-cyanopropyl)-3-
 [[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with
 trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439907-66-1
 CMF C25 H30 N3 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439907-69-4 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(cyclopropylmethyl)-3-
 [[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with
 trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-68-3
 CMF C25 H31 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439907-71-8 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-ethoxyethyl)-3-
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-70-7

CMF C25 H33 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439907-73-0 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(5-ethoxy-5-oxopentyl)-3-
 [[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with
 trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439907-72-9
 CMF C28 H37 N2 O4

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439907-75-2 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(4-phenylbutyl)-3-
 [[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with
 trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-74-1
 CMF C31 H37 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439907-77-4 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(4-fluorophenoxy)propyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-76-3

CMF C30 H34 F N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439907-79-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-hydroxypropyl)-3-
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-78-5

CMF C24 H31 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439907-81-0 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[4-(acetyloxy)butyl]-3-
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-80-9

CMF C27 H35 N2 O4


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439907-83-2 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[4-oxo-4-(2-thienyl)butyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-82-1

CMF C29 H33 N2 O3 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439907-85-4 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(3-hydroxyphenoxy)propyl]-3-
 [[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with
 trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439907-84-3
 CMF C30 H35 N2 O4

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439907-87-6 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-heptyl-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-86-5
 CMF C28 H39 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439907-89-8 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(phenylmethoxy)ethyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-88-7

CMF C30 H35 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439907-92-3 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-fluorophenyl)(phenylmethyl)amino]carbonyl]oxy]-1-(2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439907-91-2
 CMF C24 H28 F N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439907-94-5 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-fluorophenyl)(phenylmethyl)amino]carbonyl]oxy]-1-(3-phenylpropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-93-4
 CMF C30 H34 F N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439907-97-8 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-methylphenyl)(phenylmethyl)amino]carbonyl]oxy]-1-(2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-96-7

CMF C25 H31 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439907-99-0 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-methylphenyl)(phenylmethyl)amino]carbonyl]oxy]-1-(3-phenylpropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-98-9

CMF C31 H37 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6


CMF C2 F3 O2



RN 439908-00-6 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(2-methoxyethoxy)ethyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439908-01-7 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-phenylethyl)-3-
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, bromide, (3R)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439908-02-8 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-
1-[3-(2-thienyl)propyl]-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439908-03-9 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-
1-(3-phenylpropyl)-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439908-04-0 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-phenoxyethyl)-3-
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, bromide, (3R)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.



● Br⁻

RN 439908-06-2 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(3-cyanophenoxy)propyl]-3-
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-05-1

CMF C31 H34 N3 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-08-4 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(1-naphthalenyloxy)propyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-07-3


CMF C34 H37 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-10-8 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(methylphenylamino)propyl]-3-
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439908-09-5
CMF C31 H38 N3 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-12-0 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-
1-[3-(phenylthio)propyl]-, (3R)-, salt with trifluoroacetic acid (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 439908-11-9
CMF C30 H35 N2 O2 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-14-2 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-(4-oxo-4-phenylbutyl)-3-
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-13-1

CMF C31 H35 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439908-16-4 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-
 1-[3-(2,4,6-trimethylphenoxy)propyl]-, (3R)-, salt with trifluoroacetic
 acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439908-15-3
 CMF C33 H41 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439908-18-6 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(2-chlorophenoxy)propyl]-3-
 [[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with
 trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-17-5
 CMF C30 H34 Cl N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-20-0 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-1-[3-[3-(trifluoromethyl)phenoxy]propyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-19-7

CMF C31 H34 F3 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-22-2 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-([1,1'-biphenyl]-4-yloxy)propyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-21-1

CMF C36 H39 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-24-4 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(2,4-difluorophenoxy)propyl]-3-
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-23-3

CMF C30 H33 F2 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-26-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(4-methoxyphenoxy)propyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-25-5

CMF C31 H37 N2 O4


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-28-8 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-1-[3-[(5,6,7,8-tetrahydro-2-naphthalenyl)oxy]propyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-27-7

CMF C34 H41 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-30-2 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(1,3-benzodioxol-5-yloxy)propyl]-3-
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-29-9

CMF C31 H35 N2 O5


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-32-4 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-[2-(aminocarbonyl)phenoxy]propyl]-3-
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-31-3

CMF C31 H36 N3 O4


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-34-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-[3-(dimethylamino)phenoxy]propyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-33-5

CMF C32 H40 N3 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-36-8 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-[4-(acetylamino)phenoxy]propyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-35-7

CMF C32 H38 N3 O4


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-38-0 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-[4-(methoxycarbonyl)phenoxy]propyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with


trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-37-9

CMF C32 H37 N2 O5


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-40-4 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(4-nitrophenoxy)propyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-39-1

CMF C30 H34 N3 O5


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-42-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-[4-(hydroxymethyl)phenoxy]propyl]-3-
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-41-5

CMF C31 H37 N2 O4


Absolute stereochemistry.



CM 2

CRN 14477-72-6


CMF C2 F3 O2



RN 439908-45-9 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-1-(3-phenylpropyl)-, bromide, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br⁻


RN 439908-50-6 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[butylphenylamino]carbonyl]oxy]-1-methyl-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439908-49-3
CMF C19 H29 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-52-8 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[butylphenylamino)carbonyl]oxy]-1-(4-methyl-3-pentenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)
(CA INDEX NAME)

CM 1


CRN 439908-51-7
CMF C24 H37 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-54-0 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[(butylphenylamino)carbonyl]oxy]-1-(3-phenoxypropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439908-53-9
 CMF C27 H37 N2 O3

Absolute stereochemistry.




CM 2

CRN 14477-72-6
 CMF C2 F3 O2



RN 439908-55-1 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[(butylphenylamino)carbonyl]oxy]-1-(3-phenyl-2-propenyl)-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




● Br⁻

RN 439908-56-2 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-(2-propenyl)-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br⁻

RN 439908-58-4 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-(2-hydroxyethyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-57-3

CMF C20 H31 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-60-8 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[(butylphenylamino)carbonyl]oxy]-1-(1-methylethyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-59-5

CMF C21 H33 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-62-0 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[(butylphenylamino)carbonyl]oxy]-1-propyl-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-61-9


CMF C21 H33 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-64-2 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[{(butylphenylamino)carbonyl}oxy]-1-(3-cyanopropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439908-63-1
CMF C22 H32 N3 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-66-4 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[(butylphenylamino)carbonyl]oxy]-1-(cyclopropylmethyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439908-65-3
CMF C22 H33 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-68-6 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[(butylphenylamino)carbonyl]oxy]-1-(2-ethoxyethyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-67-5
CMF C22 H35 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-70-0 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[(butylphenylamino)carbonyl]oxy]-1-(5-ethoxy-5-oxopentyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-69-7

CMF C25 H39 N2 O4


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-72-2 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[(butylphenylamino)carbonyl]oxy]-1-(3-hydroxypropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-71-1

CMF C21 H33 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-74-4 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[(butylphenylamino)carbonyl]oxy]-1-[3-(1H-pyrrol-1-yl)propyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 439908-73-3

CMF C25 H36 N3 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439908-76-6 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[4-(acetyloxy)butyl]-3-
 [[(butylphenylamino)carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid
 (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439908-75-5
 CMF C24 H37 N2 O4

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439908-78-8 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[4-oxo-4-(2-thienyl)butyl]-1-[[4-oxo-4-(2-thienyl)butyl]amino]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)
 (CA INDEX NAME)

CM 1

CRN 439908-77-7
 CMF C26 H35 N2 O3 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-80-2 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-(4-phenylbutyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-79-9

CMF C28 H39 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439908-82-4 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[(butylphenylamino) carbonyl]oxy]-1-[3-(3-hydroxyphenoxy)propyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)
 (CA INDEX NAME)

CM 1


CRN 439908-81-3
 CMF C27 H37 N2 O4

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439908-84-6 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[(butylphenylamino) carbonyl]oxy]-1-heptyl-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439908-83-5
 CMF C25 H41 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-86-8 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-[2-(phenylmethoxy)ethyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)
(CA INDEX NAME)

CM 1


CRN 439908-85-7
CMF C27 H37 N2 O3

Absolute stereochemistry.



CM 2


CRN 14477-72-6
CMF C2 F3 O2



RN 439908-87-9 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[(butylphenylamino) carbonyl]oxy]-1-(2-phenylethyl)-, bromide, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439908-88-0 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[(butylphenylamino) carbonyl]oxy]-1-[2-(2-methoxyethoxy)ethyl]-, bromide, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439908-90-4 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[(butylphenylamino) carbonyl]oxy]-1-[3-(4-fluorophenoxy)propyl]-, chloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439908-91-5 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-(2-phenoxyethyl)-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439908-92-6 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-[3-(2-thienyl)propyl]-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439908-93-7 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[butylphenylamino)carbonyl]oxy]-1-(3-phenylpropyl)-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439908-95-9 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439908-97-1 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenoxypentyl)-3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439908-96-0
 CMF C28 H33 N2 O3 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439908-99-3 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenylpropyl)-3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-98-2

CMF C28 H33 N2 O2 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-01-0 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenyl-2-propenyl)-3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-00-9

CMF C28 H31 N2 O2 S


Absolute stereochemistry.
Double bond geometry unknown.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-03-2 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(phenylmethoxy)ethyl]-3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-02-1

CMF C28 H33 N2 O3 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-05-4 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(3-hydroxyphenoxy)propyl]-3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-04-3

CMF C28 H33 N2 O4 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-07-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-heptyl-3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-06-5

CMF C26 H37 N2 O2 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6


CMF C2 F3 O2



RN 439909-08-7 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-1-[3-(2-thienyl)propyl]-, bromide, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439909-09-8 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-phenoxyethyl)-3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439909-10-1 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-1-(2-propenyl)-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439909-12-3 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br⁻

RN 439909-14-5 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-1-(2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-13-4

CMF C25 H31 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-16-7 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenoxypropyl)-3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-15-6

CMF C31 H37 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-18-9 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-phenoxyethyl)-3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-17-8

CMF C30 H35 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-20-3 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-1-(3-phenylpropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 439909-19-0

CMF C31 H37 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-22-5 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-1-(3-phenyl-2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 439909-21-4

CMF C31 H35 N2 O2

Absolute stereochemistry.


Double bond geometry unknown.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-24-7 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(phenylmethoxy)ethyl]-3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-23-6

CMF C31 H37 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-26-9 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(3-hydroxyphenoxy)propyl]-3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-25-8

CMF C31 H37 N2 O4


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-29-2 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-heptyl-3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-28-1

CMF C29 H41 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-32-7 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-1-[3-(2-thienyl)propyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-31-6

CMF C29 H35 N2 O2 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6


CMF C2 F3 O2



RN 439909-36-1 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[(pentylphenylamino)carbonyl]oxy]-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439909-37-2 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[(pentylphenylamino)carbonyl]oxy]-1-(2-propenyl)-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br⁻

RN 439909-39-4 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[(pentylphenylamino)carbonyl]oxy]-1-(3-phenoxypropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-38-3


CMF C28 H39 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-41-8 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(pentylphenylamino)carbonyl]oxy]-1-(2-phenoxyethyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439909-40-7
CMF C27 H37 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-43-0 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[(pentylphenylamino)carbonyl]oxy]-1-(3-phenylpropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439909-42-9
 CMF C28 H39 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439909-45-2 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[(pentylphenylamino)carbonyl]oxy]-1-(3-phenyl-2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-44-1
 CMF C28 H37 N2 O2


Absolute stereochemistry.
 Double bond geometry unknown.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-47-4 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[(pentylphenylamino) carbonyl]oxy]-1-[2-(phenylmethoxy)ethyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-46-3

CMF C28 H39 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-49-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(3-hydroxyphenoxy)propyl]-3-[[(pentylphenylamino) carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-48-5

CMF C28 H39 N2 O4


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-51-0 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-heptyl-3-[[(pentylphenylamino)carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-50-9

CMF C26 H43 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439909-53-2 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[(pentylphenylamino) carbonyl]oxy]-1-[3-(2-thienyl)propyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439909-52-1
 CMF C26 H37 N2 O2 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439909-56-5 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[(4-pentenylphenylamino) carbonyl]oxy]-1-(2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-55-4
 CMF C22 H31 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-58-7 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[4-pentenylphenylamino)carbonyl]oxy]-1-(3-phenoxypropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-57-6

CMF C28 H37 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439909-60-1 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[4-pentenylphenylamino)carbonyl]oxy]-1-(2-phenoxyethyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439909-59-8
 CMF C27 H35 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439909-62-3 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[4-pentenylphenylamino)carbonyl]oxy]-1-(3-phenylpropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-61-2
 CMF C28 H37 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-64-5 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[(4-pentenylphenylamino) carbonyl]oxy]-1-(3-phenyl-2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 439909-63-4

CMF C28 H35 N2 O2


Absolute stereochemistry.
Double bond geometry unknown.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439909-66-7 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-pentenylphenylamino)carbonyl]oxy]-1-[2-(phenylmethoxy)ethyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439909-65-6
 CMF C28 H37 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439909-68-9 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(3-hydroxyphenoxy)propyl]-3-[[[(4-pentenylphenylamino)carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-67-8
 CMF C28 H37 N2 O4


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-70-3 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-heptyl-3-[[[4-pentenylphenylamino)carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-69-0

CMF C26 H41 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439909-72-5 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[[4-pentenylphenylamino)carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439909-71-4
 CMF C20 H29 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439909-75-8 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[4-pentenylphenylamino)carbonyl]oxy]-1-[3-(2-thienyl)propyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-74-7
 CMF C26 H35 N2 O2 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-79-2 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-1-(2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 439909-78-1

CMF C22 H27 N2 O2 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439909-81-6 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenoxypropyl)-3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439909-80-5
 CMF C28 H33 N2 O3 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439909-83-8 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenylpropyl)-3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-82-7
 CMF C28 H33 N2 O2 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-85-0 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenyl-2-propenyl)-3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-84-9

CMF C28 H31 N2 O2 S


Absolute stereochemistry.
Double bond geometry unknown.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439909-87-2 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(phenylmethoxy)ethyl]-3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439909-86-1
 CMF C28 H33 N2 O3 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439909-89-4 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(3-hydroxyphenoxy)propyl]-3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-88-3
 CMF C28 H33 N2 O4 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-91-8 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-heptyl-3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-90-7

CMF C26 H37 N2 O2 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-93-0 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-92-9

CMF C20 H25 N2 O2 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6


CMF C2 F3 O2



RN 439909-94-1 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-1-[3-(2-thienyl)propyl]-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439909-95-2 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-phenoxymethyl)-3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br⁻

RN 439910-21-1 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[cyclopentyl(2-thienylmethyl)amino]carbonyl]oxy]-1-(2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439910-20-0

CMF C21 H31 N2 O2 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439910-25-5 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[cyclopentyl(2-thienylmethyl)amino]carbonyl]oxy]-1-(3-phenylpropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439910-24-4

CMF C27 H37 N2 O2 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439910-30-2 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-furanylmethyl)phenylamino]carbonyl]oxy]-1-(2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)
 (CA INDEX NAME)

CM 1


CRN 439910-29-9
 CMF C22 H27 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439910-33-5 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-furanylmethyl)phenylamino]carbonyl]oxy]-1-(3-phenylpropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)
 (CA INDEX NAME)

CM 1

CRN 439910-32-4
 CMF C28 H33 N2 O3


Absolute stereochemistry.



CM 2


CRN 14477-72-6

CMF C2 F3 O2




RN 439910-43-7 CAPLUS

CN Carbamic acid, phenyl(phenylmethyl)-, 1-azabicyclo[2.2.1]hept-4-yl ester
(9CI) (CA INDEX NAME)



RN 439910-45-9 CAPLUS


CN Carbamic acid, phenyl(phenylmethyl)-, 1-azabicyclo[2.2.2]oct-4-yl ester
(9CI) (CA INDEX NAME)



RN 439910-49-3 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-[3-(3-hydroxyphenoxy)propyl]-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439910-50-6 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[(butylphenylamino) carbonyl]oxy]-1-[3-(4-fluorophenoxy)propyl]-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br⁻

IT 439908-43-7P


RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);
USES (Uses)

(preparation of quinuclidine carbamate derivs. as M3 antagonists)

RN 439908-43-7 CAPLUS

CN Carbamic acid, phenyl(phenylmethyl)-, (3S)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2002:10471 CAPLUS

DOCUMENT NUMBER: 136:69742

TITLE: Preparation of quinuclidinecarbamates derived from arylalkylamines as M3 muscarinic receptor antagonists

INVENTOR(S): Farrerons Gallemí, Carles; Catena Ruiz, Juan Lorenzo; Fernandez Serrat, Anna; Miquel Bono, Ignacio Jose; Balsa Lopez, Dolors; Bonilla Navarro, Jose Ignacio; Lagunas Arnal, Carmen; Salcedo Roca, Carolina; Fernandez Garcia, Andres

PATENT ASSIGNEE(S): Laboratorios S.A.L.V.A.T., S.A., Spain

SOURCE: PCT Int. Appl., 30 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Spanish


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000652	A1	20020103	WO 2001-ES252	20010625
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2414514	A1	20020103	CA 2001-2414514	20010625
AU 200166100	A	20020108	AU 2001-66100	20010625
EP 1300407	A1	20030409	EP 2001-943553	20010625
EP 1300407	B1	20040225		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001012297	A	20030506	BR 2001-12297	20010625
HU 2003001414	A2	20030929	HU 2003-1414	20010625
JP 2004501916	T	20040122	JP 2002-505776	20010625
AT 260277	T	20040315	AT 2001-943553	20010625
PT 1300407	T	20040531	PT 2001-943553	20010625
ES 2213703	T3	20040901	ES 2001-1943553	20010625
CZ 294251	B6	20041110	CZ 2003-261	20010625
AP 1420	A	20050614	AP 2003-2722	20010625
DE 20122417	U1	20050908	DE 2001-20122417	20010625
NO 2002006211	A	20030226	NO 2002-6211	20021223
MX 2003PA00141	A	20030527	MX 2003-PA141	20030107
BG 107474	A	20030930	BG 2003-107474	20030117
ZA 2003000644	A	20040210	ZA 2003-644	20030123
IN 2003CN00150	A	20050408	IN 2003-CN150	20030124
US 2004063950	A1	20040401	US 2003-312227	20030728
US 6916828	B2	20050712		
HK 1054934	A1	20041021	HK 2003-107175	20031006
US 2004235887	A1	20041125	US 2004-875592	20040623
US 7115629	B2	20061003		
IN 2007CN00210	A	20070824	IN 2007-CN210	20070118
PRIORITY APPLN. INFO.:			ES 2000-1661	A 20000627
			EP 2001-943553	A 20010625
			WO 2001-ES252	W 20010625
			IN 2003-CN150	A3 20030124
			US 2003-312227	A1 20030728

OTHER SOURCE(S): MARPAT 136:69742

GI



I

AB The quinuclidinecarbamates I [R1, R2, R3 = H, OH, SH, CN, F, Cl, Br, I, (C1-C4)-alkylthio, (C1-C4)-alkoxyl, (C1-C4)-alkoxyl substituted by one or several F radicals, carbamoylamine, (C1-C4)-alkyl and (C1-C4)-alkyl substituted by one or several F or OH radicals; R4 = a substituted or non-substituted cycloalkyl or cycloaryl radical (a heteroalkyl radical or not)] were prepared as antagonists of the M3 muscarinic receptor, and selectively, the M2 receptor. The amine of the quinuclidine ring can also be forming quaternary ammonium salts or in an oxidized state (N-oxide). I can be used in the treatment of urinary incontinence (particularly due to bladder instability), irritable bowel syndrome, diseases of the respiratory tract (particularly chronic obstructive pulmonary disease, chronic bronchitis, asthma, emphysema and rhinitis) and in ophthalmol. operations. Thus, (R)-quinuclidinol was converted to the chloroformate and reacted with N-phenylbenzylamine to give (R)-I (R1 = R2 = R3 = H, R4 = Ph) (II). The M3 muscarinic receptor constant K_i of II was 0.31 nM.


IT 385367-12-4P 385367-13-5P 385367-14-6P
 385367-15-7P 385367-16-8P 385367-17-9P
 385367-18-0P 385367-19-1P 385367-20-4P
 385367-21-5P 385367-22-6P 385367-23-7P
 385367-24-8P 385367-25-9P 385367-26-0P
 385367-27-1P 385367-28-2P 385367-29-3P
 385367-30-6P 385367-31-7P 385367-32-8P
 385367-33-9P 385367-34-0P 385367-35-1P
 385367-36-2P 385367-37-3P 385367-38-4P
 385367-39-5P 385367-40-8P 385367-41-9P
 385367-42-0P 385367-43-1P 385367-44-2P
 385367-45-3P 385367-46-4P 385367-47-5P
 385367-48-6P 385367-49-7P 385367-50-0P
 385367-51-1P 385367-52-2P 385367-53-3P
 385367-54-4P 385367-55-5P 385367-56-6P
 385367-57-7P 385367-58-8P 385367-59-9P
 385367-60-2P 385367-61-3P 385367-62-4P
 385367-63-5P 385367-64-6P 385367-65-7P
 385367-66-8P 385367-67-9P 385367-68-0P
 385367-69-1P 385367-70-4P 385367-71-5P
 385367-72-6P 385367-73-7P 385367-74-8P
 385367-75-9P 385367-76-0P 385367-78-2P
 385367-79-3P 385424-09-9P 385424-10-2P
 385424-11-3P 385424-12-4P

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinuclidinecarbamates derived from arylalkylamines as quinuclidinecarbamates)

RN 385367-12-4 CAPLUS


CN Carbamic acid, phenyl(phenylmethyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)



RN 385367-13-5 CAPLUS

CN Carbamic acid, phenyl(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 385367-14-6 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[[phenyl(phenylmethyl)amino]carbonyloxy]-, iodide, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● I⁻

RN 385367-15-7 CAPLUS


CN Carbamic acid, phenyl(phenylmethyl)-, 1-oxido-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)



RN 385367-16-8 CAPLUS

CN Carbamic acid, (2-fluorophenyl)(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-17-9 CAPLUS

CN Carbamic acid, (3-chlorophenyl)(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-18-0 CAPLUS

CN Carbamic acid, (3-bromophenyl)(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-19-1 CAPLUS

CN Carbamic acid, (2,6-difluorophenyl)(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-20-4 CAPLUS

CN Carbamic acid, (3,4-difluorophenyl)(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-21-5 CAPLUS

CN Carbamic acid, (3-methylphenyl)(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-22-6 CAPLUS

CN Carbamic acid, (2,6-dimethylphenyl)(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-23-7 CAPLUS

CN Carbamic acid, (2,3-dihydro-1H-inden-5-yl)(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-24-8 CAPLUS

CN Carbamic acid, (4-cyanophenyl)(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-25-9 CAPLUS

CN Carbamic acid, (2-hydroxyphenyl)(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-26-0 CAPLUS

CN Carbamic acid, (2-fluoro-5-methylphenyl)[(2-fluorophenyl)methyl]-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-27-1 CAPLUS

CN Carbamic acid, [(2-bromophenyl)methyl]phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-28-2 CAPLUS

CN Carbamic acid, (3-fluorophenyl)[(3-fluorophenyl)methyl]-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-29-3 CAPLUS

CN Carbamic acid, (2,3-difluorophenyl)[(2-fluorophenyl)methyl]-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-30-6 CAPLUS

CN Carbamic acid, [(4-chlorophenyl)methyl](2-fluoro-5-methylphenyl)-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-31-7 CAPLUS

CN Carbamic acid, (3-chlorophenyl)[(2,3-difluorophenyl)methyl]-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-32-8 CAPLUS

CN Carbamic acid, [(2,4-dichlorophenyl)methyl](2,4-difluorophenyl)-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-33-9 CAPLUS

CN Carbamic acid, [(2,4-difluorophenyl)methyl](3-methylphenyl)-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-34-0 CAPLUS

CN Carbamic acid, (3-chlorophenyl)[(2-fluoro-4-methoxyphenyl)methyl]-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-35-1 CAPLUS

CN Carbamic acid, (2-chlorophenyl)[(2,5-difluorophenyl)methyl]-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-36-2 CAPLUS

CN Carbamic acid, [(2-fluoro-5-methoxyphenyl)methyl]phenyl-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-37-3 CAPLUS

CN Carbamic acid, [(3,4-difluorophenyl)methyl]phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-38-4 CAPLUS

CN Carbamic acid, [(4-chloro-3-fluorophenyl)methyl](2-fluorophenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-39-5 CAPLUS

CN Carbamic acid, [(3-chloro-4-fluorophenyl)methyl]phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-40-8 CAPLUS

CN Carbamic acid, [(3,4-dichlorophenyl)methyl]phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-41-9 CAPLUS

CN Carbamic acid, [(3,5-difluorophenyl)methyl]phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-42-0 CAPLUS

CN Carbamic acid, [(3-fluoro-4-methylphenyl)methyl]phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-43-1 CAPLUS

CN Carbamic acid, [(3-fluoro-4-methoxyphenyl)methyl](2-fluorophenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-44-2 CAPLUS

CN Carbamic acid, (3-chlorophenyl)[(2,3,4-trifluorophenyl)methyl]-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-45-3 CAPLUS

CN Carbamic acid, (3-methylphenyl)[(2,3,5-trifluorophenyl)methyl]-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-46-4 CAPLUS

CN Carbamic acid, (3-methylphenyl)[(2,4,5-trifluorophenyl)methyl]-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-47-5 CAPLUS

CN Carbamic acid, (3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-48-6 CAPLUS

CN Carbamic acid, (4-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-49-7 CAPLUS

CN Carbamic acid, (3-methylphenyl)[(2-methylphenyl)methyl]-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-50-0 CAPLUS

CN Carbamic acid, phenyl[[4-(trifluoromethyl)phenyl]methyl]-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-51-1 CAPLUS


CN Carbamic acid, [(4-ethylphenyl)methyl]phenyl-, (3R)-1-azabicyclo[2.2.2]oct-
3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 385367-52-2 CAPLUS
 CN Carbamic acid, [[4-(1,1-dimethylethyl)phenyl]methyl]phenyl-,
 (3R)-1-azabicyclo[2.2.2]oct-3-yl ester. (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 385367-53-3 CAPLUS
 CN Carbamic acid, [[4-(hydroxymethyl)phenyl]methyl](2-methylphenyl)-,
 (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 385367-54-4 CAPLUS
 CN Carbamic acid, [(4-cyanophenyl)methyl]phenyl-, (3R)-1-azabicyclo[2.2.2]oct-
 3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 385367-55-5 CAPLUS
 CN Carbamic acid, [[4-(aminocarbonyl)phenyl]methyl]phenyl-,
 (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 385367-56-6 CAPLUS
 CN Carbamic acid, (2-fluorophenyl)[(2-hydroxyphenyl)methyl]-,
 (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 385367-57-7 CAPLUS
 CN Carbamic acid, [(3-hydroxyphenyl)methyl](3-methylphenyl)-,
 (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-58-8 CAPLUS

CN Carbamic acid, [(4-hydroxyphenyl)methyl]phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-59-9 CAPLUS

CN Carbamic acid, (3-chlorophenyl)[[3-(phenylmethoxy)phenyl]methyl]-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-60-2 CAPLUS

CN Carbamic acid, phenyl[[3-(trifluoromethoxy)phenyl]methyl]-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-61-3 CAPLUS

CN Carbamic acid, [[4-(1-methylethoxy)phenyl]methyl]phenyl-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-62-4 CAPLUS

CN Carbamic acid, (3-chlorophenyl)[[3-methoxy-4-(phenylmethoxy)phenyl]methyl]-
, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-63-5 CAPLUS

CN Carbamic acid, (1,3-benzodioxol-5-ylmethyl)phenyl-, (3R)-1-
azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-64-6 CAPLUS

CN Carbamic acid, [(2,3-dihydro-1,4-benzodioxin-6-yl)methyl] (3-methylphenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-65-7 CAPLUS

CN Carbamic acid, (cyclopropylmethyl)phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-66-8 CAPLUS

CN Carbamic acid, (cyclobutylmethyl)phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-67-9 CAPLUS

CN Carbamic acid, (cyclopentylmethyl)(3-methylphenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-68-0 CAPLUS

CN Carbamic acid, (cyclohexylmethyl)(2-fluorophenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-69-1 CAPLUS

CN Carbamic acid, (1-cyclohexen-1-ylmethyl)(2-fluorophenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-70-4 CAPLUS

CN Carbamic acid, (3-chlorophenyl) (3-cyclohexen-1-ylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-71-5 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-fluorophenyl)methyl]phenylamino]carbonyl]oxy]-1-methyl-, iodide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● I⁻

RN 385367-72-6 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[[(2-methylphenyl) (phenylmethyl) amino] carbonyl]oxy]-, iodide, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● I⁻

RN 385367-73-7 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[[(2-methylphenyl)[(2,4,5-trifluorophenyl)methyl]amino]carbonyl]oxy]-, iodide, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● I⁻

RN 385367-74-8 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-fluorophenyl)methyl](3-methylphenyl)amino]carbonyl]oxy]-1-methyl-, iodide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● I⁻

RN 385367-75-9 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-fluorophenyl) (phenylmethyl) amino] carbonyl]oxy]-1-methyl-, iodide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● I⁻

RN 385367-76-0 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(cyclohexylmethyl) (2-fluorophenyl) amino] carbonyl]oxy]-1-methyl-, iodide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● I⁻


RN 385367-78-2 CAPLUS
 CN Carbamic acid, phenyl(phenylmethyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 385367-79-3 CAPLUS
 CN Carbamic acid, phenyl(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



● HCl

RN 385424-09-9 CAPLUS
 CN Carbamic acid, [(4-methylcyclohexyl)methyl](3-methylphenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385424-10-2 CAPLUS

CN Carbamic acid, [[4-(1-methylethenyl)cyclohexyl]methyl](3-methylphenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385424-11-3 CAPLUS

CN Carbamic acid, (bicyclo[2.2.1]hept-2-ylmethyl)(3-fluorophenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385424-12-4 CAPLUS

CN Carbamic acid, (bicyclo[2.2.1]hept-5-en-2-ylmethyl)phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 1968:435886 CAPLUS
 DOCUMENT NUMBER: 69:35886
 ORIGINAL REFERENCE NO.: 69:6683a,6686a
 TITLE: Some quinuclidine derivatives with potential
 antimalarial activity
 AUTHOR(S): Nilsson, J. Lars G.; Wagermark, Jorgen; Dahlbom,
 Richard
 CORPORATE SOURCE: Kungl. Farm. Inst., Stockholm, Swed.
 SOURCE: Acta Pharmaceutica Suecica (1968), 5(2), 71-6
 CODEN: APSXAS; ISSN: 0001-6675
 DOCUMENT TYPE: Journal
 LANGUAGE: English

GI For diagram(s), see printed CA Issue.


AB A series of carbamates and Schiff bases were prepared with a structural
 similarity to quinine. To 3.3 g. 3-quinuclidinol in 50 ml. dry PhMe was
 added 0.6 g. powdered Na and the mixture refluxed 2 hrs. to form the
 alcoholate. N,N-Diphenylcarbamoyl chloride (6 g.) dissolved in 25 ml.
 PhMe was then slowly added, and the mixture stirred and refluxed 1 hr. to
 yield 74% 3-quinuclidinyl N,N-diphenylcarbamate, m. 79-80°. The
 following I were similarly prepared (R, % yield, and m.p. given):
 phenothiazino, 85, 183-4°; N-ethylanilino, 44, 190-2°;
 indolino, 82, 125°. II were synthesized by the usual procedure
 (same data given): diphenylmethyl, 62, 108°; 9-fluorenyl, 35,
 189-90°; cyclohexyl, 80, 75-6°. The carbamates showed
 strong anticholinergic activity both centrally and peripherally.

IT 18692-63-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 18692-63-2 CAPLUS

CN Carbanilic acid, N-ethyl-, 3-quinuclidinyl ester, monohydrochloride (8CI)
 (CA INDEX NAME)



● HCl

=> d his

(FILE 'HOME' ENTERED AT 17:39:55 ON 28 NOV 2007)

FILE 'REGISTRY' ENTERED AT 17:40:11 ON 28 NOV 2007

L1 STRUCTURE UPLOADED
L2 32 S L1
L3 587 S L1 FULL

FILE 'CAPLUS' ENTERED AT 17:40:53 ON 28 NOV 2007

L4 6 S L3 FULL

=> d his

(FILE 'HOME' ENTERED AT 17:39:55 ON 28 NOV 2007)

FILE 'REGISTRY' ENTERED AT 17:40:11 ON 28 NOV 2007

L1 STRUCTURE UPLOADED
L2 32 S L1
L3 587 S L1 FULL

FILE 'CAPLUS' ENTERED AT 17:40:53 ON 28 NOV 2007

L4 6 S L3 FULL

=> FIL STNGUIDE

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

37.26

209.57

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-4.68

-4.68

FILE 'STNGUIDE' ENTERED AT 17:48:14 ON 28 NOV 2007

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Nov 23, 2007 (20071123/UP).

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.30

209.87

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-4.68

STN INTERNATIONAL LOGOFF AT 17:51:01 ON 28 NOV 2007